(Q35110095)

6 August 2017

1 reference

title

Experience with lamivudine therapy for hepatitis B virus infection before and after liver transplantation, and review of the literature (English)

1 reference

6 August 2017

liver transplantation

1 reference

1 reference

1 reference

1 reference

https://api.crossref.org/works/10.1046/J.1365-2796.2003.01134.X

25 December 2023

author name string

Z. Ben-Ari

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12702032

25 December 2023

E. Mor

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12702032

25 December 2023

R. Tur-Kaspa

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12702032

25 December 2023

language of work or name

English

0 references

publication date

1 May 2003

1 reference

full work available at URL

6 August 2017

https://onlinelibrary.wiley.com/doi/pdfdirect/10.1046/j.1365-2796.2003.01134.x

file format

Portable Document Format

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12702032

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1046%2Fj.1365-2796.2003.01134.x

25 December 2023

1 reference

https://api.crossref.org/works/10.1046/J.1365-2796.2003.01134.X

https://onlinelibrary.wiley.com/doi/pdf/10.1046/j.1365-2796.2003.01134.x

25 December 2023

1 reference

https://api.crossref.org/works/10.1046/J.1365-2796.2003.01134.X

Journal of Internal Medicine

25 December 2023

published in

1 reference

6 August 2017

253

1 reference

6 August 2017

5

1 reference

6 August 2017

544-552

1 reference

Improved outcome of orthotopic liver transplantation for chronic hepatitis B cirrhosis with aggressive passive immunization

6 August 2017

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01134.X

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01134.X

Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01134.X

Clinical improvement in patients with decompensated liver disease caused by hepatitis B after treatment with lamivudine

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01134.X

Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01134.X

Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01134.X

Emergence of YMDD motif mutants of hepatitis B virus during lamivudine treatment of immunocompetent type B hepatitis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01134.X

Lamivudine treatment for acute hepatitis B after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01134.X

Lamivudine as first- and second-line treatment of hepatitis B infection after liver transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01134.X

A multicenter study of lamivudine treatment in 33 patients with hepatitis B after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01134.X

Viral dynamics in hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01134.X

Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipient

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01134.X

Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01134.X

Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01134.X

Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01134.X

Liver transplantation in Asian patients with chronic hepatitis B using lamivudine prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01134.X

A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01134.X

End-stage liver disease and liver transplantation: role of lamivudine therapy in patients with chronic hepatitis B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01134.X

Lamivudine after hepatitis B immune globulin is effective in preventing hepatitis B recurrence after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01134.X

Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01134.X

Lamivudine and low-dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2796.2003.01134.X

Liver transplantation in European patients with the hepatitis B surface antigen

21 January 2018

2

1 reference

https://api.crossref.org/works/10.1046/J.1365-2796.2003.01134.X

Liver transplantation and hepatitis B

25 December 2023

4

1 reference

https://api.crossref.org/works/10.1046/J.1365-2796.2003.01134.X

Hepatitis B virus reinfection after orthotopic liver transplantation. Serological and clinical implications

25 December 2023

5

1 reference

https://api.crossref.org/works/10.1046/J.1365-2796.2003.01134.X

Persistent hepatitis B virus infection of mononuclear blood cells without concomitant liver infection. The liver transplantation model.

25 December 2023

6

1 reference

https://api.crossref.org/works/10.1046/J.1365-2796.2003.01134.X

Sanctuary of hepatitis B virus in bone-marrow cells of patients undergoing liver transplantation

25 December 2023

7

1 reference

https://api.crossref.org/works/10.1046/J.1365-2796.2003.01134.X

A preliminary trial of lamivudine for chronic hepatitis B infection

25 December 2023

8

1 reference

https://api.crossref.org/works/10.1046/J.1365-2796.2003.01134.X

Inhibition of the replication of hepatitis B virus in vitro by 2',3'-dideoxy-3'-thiacytidine and related analogues

25 December 2023

9

1 reference

https://api.crossref.org/works/10.1046/J.1365-2796.2003.01134.X

Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis

25 December 2023

10

1 reference

https://api.crossref.org/works/10.1046/J.1365-2796.2003.01134.X

Beneficial effect of lamivudine in recurrent hepatitis B after liver transplantation

25 December 2023

11

1 reference

https://api.crossref.org/works/10.1046/J.1365-2796.2003.01134.X

Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. Lamivudine Transplant Group.

25 December 2023

12

1 reference

https://api.crossref.org/works/10.1046/J.1365-2796.2003.01134.X

Lamivudine as initial treatment for chronic hepatitis B in the United States

25 December 2023

13

1 reference

https://api.crossref.org/works/10.1046/J.1365-2796.2003.01134.X

Long-term experience with lamivudine therapy for hepatitis B virus infection after liver transplantation

25 December 2023

16

1 reference

https://api.crossref.org/works/10.1046/J.1365-2796.2003.01134.X

Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo

25 December 2023

17

1 reference

https://api.crossref.org/works/10.1046/J.1365-2796.2003.01134.X

Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine

25 December 2023

18

1 reference

https://api.crossref.org/works/10.1046/J.1365-2796.2003.01134.X

Hepatitis B virus precore mutants are identical in carriers from various ethnic origins and are associated with a range of liver disease severity

25 December 2023

19

1 reference

https://api.crossref.org/works/10.1046/J.1365-2796.2003.01134.X

Efficacy of lamivudine in chronic hepatitis B patients with active viral replication and decompensated cirrhosis undergoing liver transplantation

25 December 2023

20

1 reference

https://api.crossref.org/works/10.1046/J.1365-2796.2003.01134.X

Extension of transplantation free time by lamivudine in patients with hepatitis B-induced decompensated cirrhosis

25 December 2023

21

1 reference

https://api.crossref.org/works/10.1046/J.1365-2796.2003.01134.X

Identification of more than one mutation in the hepatitis B virus polymerase gene arising during prolonged lamivudine treatment

25 December 2023

26

1 reference

https://api.crossref.org/works/10.1046/J.1365-2796.2003.01134.X

Efficacy of lamivudine in controlling hepatitis B virus recurrence after liver transplantation

25 December 2023

28

1 reference

https://api.crossref.org/works/10.1046/J.1365-2796.2003.01134.X

Lamivudine therapy in patients undergoing liver transplantation for hepatitis B virus precore mutant-associated infection: high resistance rates in treatment of recurrence but universal prevention if used as prophylaxis with very low dose [...]

25 December 2023

31

1 reference

https://api.crossref.org/works/10.1046/J.1365-2796.2003.01134.X

Lamivudine for hepatitis B in liver transplantation: a single-center experience

25 December 2023

32

1 reference

https://api.crossref.org/works/10.1046/J.1365-2796.2003.01134.X

Outcome of liver transplantation for hepatitis B: report of a single center's experience

25 December 2023

35

1 reference

https://api.crossref.org/works/10.1046/J.1365-2796.2003.01134.X

Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients

25 December 2023

37

1 reference

https://api.crossref.org/works/10.1046/J.1365-2796.2003.01134.X

Hepatitis B virus DNA contains a glucocorticoid-responsive element

25 December 2023

38

1 reference

https://api.crossref.org/works/10.1046/J.1365-2796.2003.01134.X

Association of lamivudine resistance in recurrent hepatitis B after liver transplantation with advanced hepatic fibrosis

25 December 2023

40

1 reference

https://api.crossref.org/works/10.1046/J.1365-2796.2003.01134.X

Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro

25 December 2023

44

1 reference

https://api.crossref.org/works/10.1046/J.1365-2796.2003.01134.X

De novo hepatitis B infection acquired during liver transplantation

25 December 2023

46

1 reference

https://api.crossref.org/works/10.1046/J.1365-2796.2003.01134.X

Prevention of de novo hepatitis B infection after liver transplantation with allografts from hepatitis B core antibody positive donors

25 December 2023

47

1 reference

https://api.crossref.org/works/10.1046/J.1365-2796.2003.01134.X

De novo hepatitis B infection after liver transplantation: source of disease, incidence, and impact

25 December 2023

48

1 reference

https://api.crossref.org/works/10.1046/J.1365-2796.2003.01134.X

Severe clinical course of de novo hepatitis B infection after liver transplantation

25 December 2023

49

1 reference

https://api.crossref.org/works/10.1046/J.1365-2796.2003.01134.X

Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis.

25 December 2023

50

1 reference

https://api.crossref.org/works/10.1046/J.1365-2796.2003.01134.X

Incidence and clinical consequences of surface and polymerase gene mutations in liver transplant recipients on hepatitis B immunoglobulin.

25 December 2023

51

1 reference

https://api.crossref.org/works/10.1046/J.1365-2796.2003.01134.X

Hepatitis B virus with antigenically altered hepatitis B surface antigen is selected by high-dose hepatitis B immune globulin after liver transplantation

25 December 2023

52

1 reference

https://api.crossref.org/works/10.1046/J.1365-2796.2003.01134.X

Lamivudine without HBIg for prevention of graft reinfection by hepatitis B: long-term follow-up

25 December 2023

53

1 reference

https://api.crossref.org/works/10.1046/J.1365-2796.2003.01134.X

Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin

25 December 2023

56

1 reference

https://api.crossref.org/works/10.1046/J.1365-2796.2003.01134.X

An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy

25 December 2023

60

1 reference

https://api.crossref.org/works/10.1046/J.1365-2796.2003.01134.X

Liver transplantation for chronic hepatitis B infection with the use of combination lamivudine and low-dose hepatitis B immune globulin

25 December 2023

61

1 reference

https://api.crossref.org/works/10.1046/J.1365-2796.2003.01134.X

25 December 2023

Identifiers

1 reference

6 August 2017

1 reference